- Home
- BRTX vs DRCT Comparison
BRTX vs DRCT Comparison
Compare BRTX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- DRCT
- Stock Information
- Founded
- BRTX 1997
- DRCT 2018
- Country
- BRTX United States
- DRCT United States
- Employees
- BRTX N/A
- DRCT 79
- Industry
- BRTX Managed Health Care
- DRCT Computer Software: Programming Data Processing
- Sector
- BRTX Health Care
- DRCT Technology
- Exchange
- BRTX Nasdaq
- DRCT Nasdaq
- Market Cap
- BRTX 12.2M
- DRCT 11.2M
- IPO Year
- BRTX N/A
- DRCT 2022
- Fundamental
- Price
- BRTX $1.71
- DRCT $0.67
- Analyst Decision
- BRTX Strong Buy
- DRCT
- Analyst Count
- BRTX 1
- DRCT 0
- Target Price
- BRTX $18.00
- DRCT N/A
- AVG Volume (30 Days)
- BRTX 34.3K
- DRCT 1.1M
- Earning Date
- BRTX 05-13-2025
- DRCT 03-27-2025
- Dividend Yield
- BRTX N/A
- DRCT N/A
- EPS Growth
- BRTX N/A
- DRCT N/A
- EPS
- BRTX N/A
- DRCT N/A
- Revenue
- BRTX $401,000.00
- DRCT $62,288,000.00
- Revenue This Year
- BRTX $446.88
- DRCT $53.01
- Revenue Next Year
- BRTX $39.53
- DRCT $11.11
- P/E Ratio
- BRTX N/A
- DRCT N/A
- Revenue Growth
- BRTX 175.03
- DRCT N/A
- 52 Week Low
- BRTX $1.03
- DRCT $0.44
- 52 Week High
- BRTX $2.55
- DRCT $7.68
- Technical
- Relative Strength Index (RSI)
- BRTX 46.37
- DRCT 50.52
- Support Level
- BRTX $1.64
- DRCT $0.53
- Resistance Level
- BRTX $1.78
- DRCT $0.74
- Average True Range (ATR)
- BRTX 0.10
- DRCT 0.10
- MACD
- BRTX -0.01
- DRCT 0.02
- Stochastic Oscillator
- BRTX 42.82
- DRCT 77.42
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.